Table 2.
Bacteria targeted | Route of administration | Challenge method | Ref. | |
---|---|---|---|---|
Antigens | ||||
Killed whole cell | Burkholderia mallei | sc. | ip. | [37] |
Attenuated live whole cell | B. mallei and B. pseudomallei | Aerogenic, ip., in. | Aerosol, ip., ip. | [39,41,61] |
LPS | B. pseudomallei | ip. | ip. or in. | [50,62] |
CP | B. pseudomallei | ip. | ip. or in. | [50,62] |
Pili | B. mallei | sc. | Aerosol | [63] |
Outer membrane proteins | B. pseudomallei | ip. | ip. | [64] |
Type III secretion system subunits | B. pseudomallei | ip. | ip. | [65] |
Immunotherapies and other treatments | ||||
IL-12 with killed whole cells | B. mallei | sc. | ip. | [38] |
Monoclonal antibodies to LPS | B. mallei | ip. | Aerosol | [51,66] |
Monoclonal antibody cocktail to LPS, CP and proteins | B. pseudomallei | iv. | ip. | [51,66] |
CpG oligodeoxynucleotide | B. mallei | ip. | Aerosol | [67] |
Primed dentritic cells with CpG | B. pseudomallei | id. | ip. | [68] |
DNA encoding fagellin | B. pseudomallei | im. | iv. | [69] |
CP: Capsular polysaccharide; id.: Intradermal; im.: Intramuscular; in.: Intranasal; ip.: Intraperitoneal; iv.: Intravenous; LPS: Lipopolysaccharide; sc.: Subcutaneous.